Antigen-experienced CD4+ T cells limit naïve T-cell priming in response to therapeutic vaccination in vivo

Cancer Research

Volumn 70, Issue 15, 2010, Pages 6161-6170

  Schiering, Chris ^a,b,c   Guarnerio, Jlenia ^a   Basso, Veronica ^a   Muzio, Luca ^a   Mondino, Anna ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER SURGERY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOGENICITY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINATION; VACCINE FAILURE;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, PROTOZOAN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; IMMUNODOMINANT EPITOPES; INBREEDING; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTOZOAN PROTEINS; TREATMENT FAILURE;

EID: 77955375908     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4398     Document Type: Article

References (54)

1. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells:March 2004 update. Cancer Immunol Immunother 2005;54:187-207.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
3. MacLeod MK, Clambey ET, Kappler JW, Marrack P. CD4 memory T cells: what are they and what can they do? Semin Immunol 2009;21:53-61.
4. + T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
5. + T lymphocytes: a critical component of antitumor immunity. Cancer Invest 2005;23:413-9.
6. + T cells. Curr Opin Immunol 2009;21:200-8.
7. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000;164:3902-12.
8. + T cell to a fully functional tumor killer cell. Cancer Res 2002;62:6438-41.
9. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9. (Pubitemid 36433726)
10. + T cells. J Immunol 2008;181:4363-70.
11. + T cells. J Immunol 2008;180:3122-31.
12. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc Natl Acad Sci U S A 1999;96:8633-8.
13. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 2000;12:677-86.
14. + T cells differentiated in vivo eradicate established melanoma. J Exp Med 2005;207:651-67.
15. + helper T cells induces potent primary and secondary tumor rejection. Blood 2005;106:2995-3003.
16. + T cell-directed dendritic cell vaccination. J Immunol 2007;179:2899-909.
17. + T cell-targeted antigen-presenting cells elicit protective antitumor responses. Cancer Res 2008;68:3010-8.
18. + T cells. Eur J Immunol 2005;40:470-9.
19. Benigni F, Zimmermann VS, Hugues S, et al. Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. J Immunol 175:739-48.
20. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
21. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
22. + T cells in cancer immunotherapy. Curr Opin Immunol 1994;6:741-5.
23. + T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
24. + T cells have a major "Post-Licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-55.
25. Klein L, Trautman L, Psarras S, et al. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol 2003;33:806-14. (Pubitemid 36367684)
26. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
27. - and IL-2-dependent mechanism. Immunity 1999;11:483-93.
28. Wick M, Dubey P, Koeppen H, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997;186:229-38. (Pubitemid 27328023)
29. + T cells in resistant mice upon infection with Leishmania major. Immunity 2000;13:771-82.
30. Nanni P, de Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983;1:373-80. (Pubitemid 14221672)
31. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003;63:3688-94.
32. Johansen P, Haffner AC, Koch F, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005;35:568-74.
33. Millrain M, Chandler P, Dazzi F, Scott D, Simpson E, Dyson PJ. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J Immunol 2001;167:3756-64. (Pubitemid 32910821)
34. + killer T cells. J Immunol 1990;144:790-5.
35. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon γ is required for activation-induced death of T lymphocytes. J Exp Med 2002;196:999-1005.
36. + Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002;169:1593-603.
37. + CTL. J Exp Med 2005;202:1109-19.
38. + T cells: ready for direct attack. J Exp Med 2006;203:805-8.
39. MartIn-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003;198:615-21.
40. Henrickson SE, von Andrian UH. Single-cell dynamics of T-cell priming. Curr Opin Immunol 2007;19:249-58.
41. Kedl RM, Kappler JW, Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 2003;15:120-7. (Pubitemid 35454202)
42. + T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells. Immunol Cell Biol 2004;82:103-11.
43. Thomson CW, Lee BP, Zhang L. Double-negative regulatory T cells: non-conventional regulators. Immunol Res 2006;35:163-78.
44. + T cell responses. J Immunol 2009;182:193-206.
45. Manca F. Selective functional depletion of HIV gp120 peptides complexed with MHC from antigen-presenting cells engaged with specific T lymphocytes. J Immunol 1992;149:796-800.
46. Vidovic D, Falcioni F, Bolin DR, Nagy ZA. Down-regulation of class II major histocompatibility complex molecules on antigen presenting cells after interaction with helper T cells. Eur J Immunol 1995;25:1326-31.
47. Lake RA, Robinson BW, Hayball JD. MHC multimerization, antigen expression and the induction of APC amnesia in the developing immune response. Immunol Cell Biol 1999;77:99-104.
48. Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, et al. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution. Br J Haematol 2005;128:73-81.
49. + CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genomewide analysis. J Exp Med 2008;205:2863-72.
50. + T cells induce perforin-dependent dendritic cell death in tumordraining lymph nodes. Immunity 2010;32:266-78.
51. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
52. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995;146:57-79.
53. + T cells. Cell Immunol 2009;257:69-79.
54. Merica R, Khoruts A, Pape KA, Reinhardt RL, Jenkins MK. Antigen-experienced CD4 T cells display a reduced capacity for clonal expansion in vivo that is imposed by factors present in the immune host. J Immunol 2000;164:4551-7. (Pubitemid 30238051)